

# A systematic review of barriers to delivery of thrombolysis for acute stroke

JOSEPH KWAN<sup>1</sup>, PETER HAND<sup>2</sup>, PETER SANDERCOCK<sup>3</sup>

<sup>1</sup>University Department of Geriatric Medicine, Level E (MP807), Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK

<sup>2</sup>Department of Neurology, Royal Melbourne Hospital, Grattan Street, Parkville, VIC 3050, Australia

<sup>3</sup>\*Department of Clinical Neurosciences, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK

\*Place the work was undertaken

Address correspondence to: J. Kwan. Fax: (+44) 2380 796128. Email: jk@lto1.org

## Abstract

**Background and purpose:** barriers within the patient pathway can prevent early administration of thrombolytic therapy in patients admitted with acute stroke. This systematic review aimed to identify such barriers that have been reported in the medical literature.

**Methods:** we searched MEDLINE and EMBASE for prospective and retrospective observational studies that assessed the nature of barriers to delivery of thrombolysis for acute stroke.

**Results:** we identified 54 eligible studies (including a total of 39,030 patients). The reported barriers included: (i) the patient or family did not recognise symptoms of stroke or seek urgent help, (ii) the general practitioner (rather than an ambulance) was called first, (iii) the paramedics and emergency department staff triaged stroke as non-urgent, (iv) delays in neuroimaging, (v) inefficient process of in-hospital emergency stroke care, (vi) difficulties in obtaining consent for thrombolysis, and (vii) physicians' uncertainty about administering thrombolysis.

**Conclusions:** we identified important pre-hospital and in-hospital barriers that should be overcome if thrombolysis is to be administered to stroke patients efficiently and equitably.

**Keywords:** stroke, hospitalisation, medical systems, hospital, thrombolytic therapy, CVA

## Introduction

Animal studies showed that the earlier acute treatments can be given to stroke victims, the more effective they may be [1]. This led to the concept of 'time is brain'. For ischaemic stroke, therefore, the main objective of treatment is to restore blood flow as soon as possible after arterial occlusion [2]. For some patients, the benefits of thrombolysis using recombinant tissue plasminogen activator (rt-PA) within 3 hours of onset may be substantial [3]. Alteplase, a form of rt-PA, has recently been given a limited European license to be used for treatment of acute ischaemic stroke within 3 hours of onset.

In a recent observational study of 739 stroke patients in 22 hospitals across the UK, as many as 37% of all patients arrived at the hospital within 3 hours of symptom onset [4]. This figure is comparable to those reported by studies from other countries [5–7]. However, due to delays along the

patient pathway, only a small proportion of stroke patients actually receive thrombolytic therapy [8, 9]. Thrombolysis could therefore only be routinely administered if specific barriers are identified and successfully overcome. This systematic review – part of an NHS Health Technology Assessment (HTA) Project on acute stroke care [10] – aimed to describe such barriers that have been reported in the medical literature.

## Methods

The details of the methods have been reported in full elsewhere [10]. In summary, we sought prospective and retrospective observational studies that assessed the nature or duration of barriers to thrombolysis for acute stroke. We excluded the following types of publications: (i) those that were not original research, (ii) studies that observed only

those patients who received rt-PA, (iii) surveys of opinions, and (iv) studies of very specialised groups of stroke patients.

We searched MEDLINE and EMBASE from 1990 to early 2001. The detailed version of the search strategy is available in the original NHS HTA report [10]. Titles, keywords and abstracts of all downloaded citations were screened and paper copies of those meeting our selection criteria were retrieved. Two reviewers (JK, PAGS) independently assessed the methodological quality of all included studies and recorded their findings. Two reviewers (JK, PH) then extracted the data onto a pre-defined data extraction form.

## Results

We scanned 18,561 titles and abstracts and retrieved 112 publications in full text. From these, we included 54 studies that reported data on barriers to delivery of thrombolysis for acute stroke. In general, these studies covered one or more of three areas: (i) delays in the patient pathway, (ii) specific barriers to delivery of thrombolysis, and (iii) proportion of patients who were eligible for thrombolysis.

### Quality of the studies

We found 54 observational studies (with 39,030 patients). Fifteen studies stated that patients were consecutively recruited [11–25]. Three studies recruited only patients with ischaemic strokes [8, 26, 27] and one study recruited only patients with first-ever strokes [28]. Fifty-two studies were hospital based and two studies were community based [21, 29]. Twenty-three studies were conducted in the USA or Canada, 20 in Europe (of which five were in the UK), six in Asia, two in Israel, two in Australia or New Zealand, and one in South America.

### Delays in the patient pathway

Detailed results of the included studies are reported as supplementary data (available at <http://www.ageing.oup-journals.org>). In summary, the reported in-hospital delays included: (i) from stroke onset to arrival at hospital, and (ii) from arrival at hospital to first medical assessment, CT brain scan, neurologist assessment, ward admission and administration of thrombolysis.

Nine studies reported mean delay time from stroke onset to arrival at hospital [19, 20, 30–36]. The majority of the reported mean delays were between 2 and 6 hours but these varied widely, ranging from  $1.9 \pm 1.3$  hours (mean  $\pm$  standard deviation, SD) [30] to  $12.2 \pm 2$  hours [19] to  $29 \pm 53.8$  hours [20]. Eight studies reported mean delay time from arrival at hospital to CT scan [26, 27, 30, 32–34, 37, 38]. The majority of the reported mean delays were between 20 minutes and four hours but these again varied widely, ranging from  $0.3 \pm 0.3$  hours [33] to 15.1 hours (no SD) [37] to  $58 \pm 41$  hours [26].

Twenty-nine studies reported the proportions of patients arriving at hospital within various timeframes (see Table 1) [5–7, 11, 14, 17–22, 25, 27–29, 31, 32, 34, 35, 39–48]. In the UK, the proportion of patients arriving within 3 hours of stroke onset ranged from 25% [48] to 31% [40],

which is comparable to the more recently published findings of Harraf *et al.* [4]. In the USA, where Alteplase has been licensed for use in acute stroke since 1995, this proportion appears to be larger, ranging from 30% [6] to 56% [34].

### Specific barriers to delivery of thrombolysis for acute stroke

Detailed results of the studies are reported as supplementary data. In summary, we identified the following nine types of barriers.

(i) *The patient or family did not recognise symptoms of stroke or seek urgent help:* Twenty-one studies identified this as a barrier [6, 11, 13, 16–18, 20, 23, 31–33, 35, 36, 40, 42–46, 49, 50]. The commonest factors associated with it were: (i) patient living alone or was retired [11, 20, 31, 42, 45, 49], (ii) symptoms not recognised or not interpreted as stroke [13, 20, 35, 43, 44, 46], (iii) lack of bystander witness when stroke symptoms occurred [13, 16, 32, 49], (iv) patient or family not seeking medical help at all [6, 18, 23], (v) patient or family having no sense of urgency to seek help when symptoms started [20, 23, 33, 36, 43, 49], (vi) stroke symptoms started at home [40], and (vii) patient refused to go to hospital [20].

(ii) *Patient or family did not call an ambulance:* Twenty-three studies identified this as a barrier [6, 14, 16, 18, 20–23, 27, 28, 32–34, 36, 40, 42, 43, 46, 48–52]. These studies found that ambulance transfer was associated with a shorter delay to arrival at hospital, whereas first contacting a general practitioner (GP) increased the delay. One study observed that four groups of patients were particularly likely to arrive by ambulance: (a) patients living with someone else, (b) if a witness was present at stroke onset, (c) older patients, and (d) patients with haemorrhagic strokes [49]. Fourteen studies reported the proportion of patients who arrived by ambulance [6, 14, 16, 20, 22, 23, 36–38, 40, 47, 50, 52, 53]. This was generally about 50%, ranging from 38% [52] to 65% [14].

(iii) *Paramedical staff did not triage stroke as an emergency:* We found seven studies that evaluated delays from calling the emergency services to the time of ambulance arrival, and from ambulance arrival at the patient to reaching the hospital [6, 18, 20, 40, 47, 48, 54]. These studies found that stroke was often not regarded as an emergency by the paramedical staff, leading to slower ambulance transfer.

(iv) *Emergency department did not triage stroke as an emergency:* We found 27 studies that examined delay from stroke onset (or arrival at hospital) to first medical assessment, neurologist's assessment, or alerting the acute stroke team [6, 12–14, 16, 18, 20, 23, 26, 30, 32–34, 37–40, 42, 44, 47–49, 51, 54–57]. The median delay from arrival at hospital to first medical assessment varied considerably, ranging from 20 minutes [49] to 4 hours [13].

(v) *Delay in neuroimaging:* We found 22 studies that evaluated delay from stroke onset (or arrival at hospital) to the first CT scan [6, 7, 12, 16, 18–20, 22, 26, 27, 29, 30, 32–34, 37–39, 45, 48, 54, 56]. Delays occurred in: requesting the scan, transporting the patient to the radiology department, carrying

**Table 1.** Delay from stroke onset to arriving at hospital: proportions of patients arriving within 3 and 6 hours (studies are grouped according to continent and country)

Study	Continent	Country	% of patients arriving <3 h	% of patients arriving <6 h
Liu et al. 1995 [25]	Asia	China	50	65
Wang et al. 1997 [7]	Asia	China	24	35
Kay et al. 1992 [45]	Asia	Hong Kong	–	– (63 <12 h)
Siu et al. 1999 [18]	Asia	Hong Kong	52	–
Yoneda et al. 2000 [27]	Asia	Japan	34	–
Charleston et al. 1999 [39]	Australia/NZ	Australia	52	64
Anderson et al. 1995 [29]	Australia/NZ	New Zealand	– (52 <4 h)	–
Jorgensen et al. 1996 [11]	Europe	Denmark	– (25 <3.5 h)	35
Rasmussen et al. 2000 [21]	Europe	Denmark	38	53
Fogelholm et al. 1996 [28]	Europe	Finland	–	43
Lannehoa et al. 1999 [32]	Europe	France	60	77
Collins et al. 1999 [19]	Europe	Ireland	25	–
Azzimondi et al. 1997 [5]	Europe	Italy	43	56
Pistollato et al. 1996 [35]	Europe	Italy	61	80
Casetta et al. 1999 [31]	Europe	Italy	– (41 <2 h)	54 (<4 h)
Fiorelli et al. 1999 [22]	Europe	Italy	34	54
Ferro et al. 1994 [20]	Europe	Portugal	–	42
Harper et al. 1992 [42]	Europe	UK	27	49
Salisbury et al. 1998 [40]	Europe	UK	31	46
Johnston et al. 1999 [48]	Europe	UK	25	47
Streifler et al. 1998 [17]	Israel	Israel	26	54
Alberts et al. 1990 [43]	USA/Canada	USA	–	– (42 <24 h)
Biller et al. 1993 [44]	USA/Canada	USA	53	63
Smith et al. 1998 [41]	USA/Canada	USA	50	66
Kothari et al. 1999 [6]	USA/Canada	USA	30	40
Morris et al. 2000 [34]	USA/Canada	USA	56	–
Engelstein et al. 2000 [47]	USA/Canada	USA	– (6.5 <2 h)	–
Duncan et al. 2000 [46]	USA/Canada	USA	50	65
Lacy et al. 2001 [14]	USA/Canada	USA	46	61

out the scan, and reporting the scan by a neuroradiologist [12, 54].

(vi) *Inefficient process of in-hospital emergency stroke care:* We found 18 studies that evaluated delay from stroke onset (or arrival at hospital) to first medical assessment, neurologist’s assessment, or ward transfer [6, 13, 16, 18, 20, 26, 30, 34, 37–39, 44, 48, 49, 51, 54–56]. Reported reasons for delay in ward transfer included beds being unavailable and delay in obtaining a porter to transport the patient [56].

(vii) *Difficulties in obtaining informed consent for thrombolysis:* In the acute phase, many stroke patients have language impairment or reduced consciousness, which makes it difficult to get their consent for treatment. Two studies identified this barrier. In one study, 10% of patients did not receive the treatment because they refused consent [56], whereas only 0.4% of patients refused in another study [24].

(viii) *Physicians’ uncertainty in administering rt-PA:* In the USA, where rt-PA is licensed, one study in 1998 found that only 16% of neurologists had ever administered the treatment [58]. In this review, one study showed that some physicians were reluctant to administer rt-PA because of conflicting trial results and difficulty in starting treatment within 3 hours of stroke onset [39]. Another study found that some physicians were uncertain of the diagnosis of acute stroke in some patients, and this uncertainty led to delayed treatments [48].

(ix) *Other identified barriers:* Five studies reported other barriers: (a) delays in retrieving old medical records, performing phlebotomy, and acquiring the drug from pharmacy [12], (b) delays in transferring the patient from another hospital [26], (c) inadequate training in stroke for doctors [48], and (d) low accuracy of stroke diagnosis by paramedical staff [59, 60].

**Proportion of stroke patients eligible for thrombolysis**

Nine studies assessed the proportion of stroke patients who were potentially or actually eligible for thrombolytic therapy with rt-PA within 3 hours of stroke onset (see Table 2) [8, 9, 19, 22, 24, 27, 47, 56, 61]. One other study assessed the proportion of patients eligible for streptokinase therapy within 6 hours of onset [54]. The proportion varied widely, ranging from 0% [47] to 22% [24]. The five commonest reasons for being ineligible for rt-PA are summarised in Table 3.

**Discussion**

**Methodological aspects**

The identified studies were variable in quality, sample size, and study population. Many had substantial methodological weaknesses and were open to bias, precluding a meaningful quantitative meta-analysis of either the frequency or impact

**Table 2.** Proportions of stroke patients who were potentially or actually eligible for thrombolytic therapy with rt-PA within 3 hours of onset (studies are grouped according to continent and country)

Study	Continent	Country	% eligible
Yoneda <i>et al.</i> 2000 [27]	Asia	Japan	9
Grond <i>et al.</i> 1998 [24]	Europe	Germany	22
Collins <i>et al.</i> 1999 [19]	Europe	Ireland	6
Fiorelli <i>et al.</i> 1999 [22]	Europe	Italy	14
Andre <i>et al.</i> 1998 [56]	S. America	Brazil	9
Zweifler <i>et al.</i> 1998 [9]	USA/Canada	USA	3.7
Chiu <i>et al.</i> 1998 [61]	USA/Canada	USA	3
O'Connor <i>et al.</i> 1999 [8]	USA/Canada	USA	2.8
Engelstein <i>et al.</i> 2000 [47]	USA/Canada	USA	0

**Table 3.** Commonest reasons for being ineligible for thrombolysis using rt-PA, and the proportions of patients who were ineligible for these reasons

Reason for being ineligible for rt-PA therapy	Proportion (% range)
Delay to treatment >3 hours, or onset time unknown	22–94
CT scan shows haemorrhage or signs of extensive infarction	10–22
Clinical signs of stroke too mild or resolving rapidly	9–19
Medical contraindications to rt-PA	6–10
Refusal to consent to treatment	0.4–10

of specific barriers [62]. Summation of such confounded data would lead to unreliable aggregate results that are difficult to interpret and unable to influence one’s practice. However, there was at least consistency in the reporting of the key barriers across a variety of healthcare settings. It is worth noting that although 39 of the 54 included studies did not recruit consecutive stroke patients, there was no apparent difference in the findings of these studies compared to the 15 studies that recruited consecutive patients. This may be because the majority of the studies recruited large numbers (hundreds) of patients and random errors might be minimised.

This systematic review was conducted in early 2001 and the search has been updated in 2003. The latest search has identified a further 32 studies of barriers to delivery of thrombolysis. We have not presented the results of these studies in this report because they are generally in line with those summarised here (references of these studies are available from the authors).

**Pre-hospital barriers**

The most consistently reported pre-hospital barrier was the patient’s or family’s poor knowledge of stroke which delayed their request for urgent medical help. Surveys have shown that many people do not know the presenting symptoms of stroke [63–65]. Even with adequate knowledge, the public has to be convinced that the emergency services, and not the GP, should be called when a person is suspected to have a brain attack. In the UK, where the majority of the hospitals do not provide a routine thrombolysis service for acute

stroke, many patients are transported to the hospital early but not immediately [4]. The many barriers identified in this review, combined with the imprecision of the magnitude of risks and benefits with rt-PA treatment, may further hinder the widespread introduction of thrombolysis despite the newly granted license of Alteplase.

**In-hospital barriers**

The most common and consistently reported sources of delay were in: (i) medical assessment, (ii) neuroimaging, and (iii) transferring the patient to the ward. Measures to overcome these in-hospital barriers could include, e.g. training of emergency department staff to triage stroke as an emergency, improving access to CT scanning and training of stroke unit staff in administering thrombolysis.

Although many stroke patients arrive in the hospital within 3 hours of onset [4], unless they are triaged as high priority to be assessed and managed quickly, thrombolysis is unlikely to have a major impact on outcome [66]. Specific interventions, such as those designed to reduce the time to alerting the acute stroke team and transferring the patient to the neuroradiology department, might increase the use of thrombolysis [67].

In conclusion, this report provides a useful checklist of potential barriers to delivery of thrombolysis for acute stroke. These barriers could be assessed in future audits of local stroke services. Further research is needed to find the best methods of reorganising emergency stroke care so that thrombolysis could be administered effectively, efficiently and equitably.

**Key points**

- The benefits of thrombolysis using intravenous recombinant tissue plasminogen activator (rt-PA) within 3 hours of onset of stroke can be substantial.
- Barriers within the patient pathway can prevent the early administration of rt-PA.
- This systematic review has identified important pre-hospital and in-hospital barriers that should be overcome if thrombolysis is to be delivered effectively, efficiently and equitably.

**Acknowledgements**

We would like to thank the staff at the Cochrane Stroke Group Editorial Base in Edinburgh for their assistance with this systematic review.

**Funding**

The review was supported by a grant from the NHS Health Technology Assessment (HTA) Programme (Grant 98/02/02).

**Possible conflicts of interest**

The opinions and views expressed do not necessarily reflect those of the NHS Executive. Potential conflict of interest: Professor Peter Sandercock: (1) is a Co-principal Investigator

for the third International Stroke Trial (IST3) of thrombolysis in acute stroke. The start-up phase of trial (2000–2002) was funded by a grant from the Stroke Association. The expansion phase of the trial (2003–2005) is supported by a grant from the PPP Healthcare Trust. Other support has consisted of a donation of trial drug and placebo from Boehringer Ingelheim for the first 300 patients to be included in the start-up phase, and help from DESACC Ltd with image analysis aspects of the study. (2) is co-ordinating editor of the Cochrane Stroke Review Group. (3) is a member of the NHS Health Technology Assessment Commissioning Board.

## References

1. Jones TH, Morawetz RB, Crowell RM *et al.* Thresholds of focal cerebral ischemia in awake monkeys. *J Neurosurg* 1981; 54: 773–82.
2. Adams HP Jr. Treating ischemic stroke as an emergency. *Arch Neurol* 1998; 55: 457–61.
3. Wardlaw JM, del Zoppo G, Yamaguchi T. Thrombolysis for acute ischaemic stroke (Cochrane systematic review). In *The Cochrane Library*, Issue 4. Oxford: Update Software, 2002.
4. Harraf F, Sharma AK, Brown MM, Lees KR, Vass RI, Kalra L. A multicentre observational study of presentation and early assessment of acute stroke. *Br Med J* 2002; 325: 17–20.
5. Azzimondi G, Bassein L, Fiorani L *et al.* Variables associated with hospital arrival time after stroke. Effect of delay on the clinical efficiency of early treatment. *Stroke* 1997; 28: 537–42.
6. Kothari R, Jauch E, Broderick J *et al.* Acute stroke: delays to presentation and emergency department evaluation. *Ann Emerg Med* 1999; 33: 3–8.
7. Wang XD, Guo H, Zhang XY, Zhu H, Li YH, Zhou G. An observation on the time of hospital arrival and correct diagnosis with CT in acute cerebral stroke patients. *Cerebrovasc Dis* 1997; 7: 89–93.
8. O'Connor RE, McGraw P, Edelsohn L. Thrombolytic therapy for acute ischemic stroke: why the majority of patients remain ineligible for treatment. *Ann Emerg Med* 1999; 33: 9–14.
9. Zweifler RM, Brody ML, Graves GC *et al.* Intravenous t-PA for acute ischaemic stroke: therapeutic yield of a code stroke system. *Neurology* 1998; 50: 501–3.
10. Sandercock P, Berge E, Dennis M *et al.* A systematic review of the effectiveness, cost-effectiveness and barriers to implementation of thrombolytic and neuroprotective therapy for acute ischaemic stroke in the NHS. *Health Technol Assess* 2002; 6: 1–112.
11. Jorgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Factors delaying hospital admission in acute stroke. The Copenhagen Stroke Study. *Neurology* 1996; 47: 383–7.
12. Tilley BC, Lyden PD, Brott TG, Lu M, Levine SR, Welch KMA. Total quality improvement method for reduction of delays between emergency department admission and treatment of acute ischaemic stroke. *Arch Neurol* 1997; 54: 1466–74.
13. Feldmann E, Gorgon N, Brooks JM *et al.* Factors associated with early presentation of acute stroke. *Stroke* 1993; 24: 1805–10.
14. Lacy CR, Suh DC, Bueno M, Kostis JB. Delay in presentation and evaluation for acute stroke: Stroke Time Registry for Outcomes Knowledge and Epidemiology (S.T.R.O.K.E.). *Stroke* 2001; 32: 63–9.
15. Gomez CR, Malkoff MD, Sauer CM, Tulyapronchote R, Burch CM, Banet GA. Code stroke. An attempt to shorten in-hospital therapeutic delays. *Stroke* 1994; 25: 1920–23.
16. Wester P, Radberg J, Lundgren B, Peltonen M. Factors associated with delayed admission to hospital and in-hospital delays in acute stroke and TIA: a prospective, multicenter study. *Stroke* 1999; 30: 40–8.
17. Streifler JY, Davidovitch S, Sendovski U. Factors associated with the time of presentation of acute stroke patients in an Israeli community hospital. *Neuroepidemiology* 1998; 17: 161–6.
18. Siu YC, Wong TW, Lau CC. Candidates for thrombolytic treatment in acute ischaemic stroke – where are our patients in Hong Kong? *J Accid Emerg Med* 1999; 16: 412–17.
19. Collins DR, O'Neill D, McCormack PME. Potential for treatment with thrombolysis in an Irish stroke unit. *Irish Med J* 1999; 92: 236–8.
20. Ferro JM, Melo TP, Oliveira V, Crespo M, Canhao P, Pinto AN. An analysis of the admission delay of acute strokes. *Cerebrovasc Dis* 1994; 4: 72–5.
21. Rasmussen BH, Germer U, Olsen TS. Acute stroke: dial 112 or call your “GP”? *Eur J Neurol* 2000; 7: 110 [Abstract P3018].
22. Fiorelli M, Falcou A, Sacchetti ML *et al.* The Rome emergency departments network for acute stroke: pilot study on incidence, referral pathways, and eligibility for thrombolytic therapy in Rome urban area. *Ital J Neurol Sci* 1999; 20: S137 [Abstract 173].
23. Ravindrane A, Croft-Baker J, Jarrett D, Severs MP. Causes of delay in hospital assessment after stroke. *Age Ageing* 2000; 29 (Suppl 2): 57.
24. Grund M, Stenzel C, Schumullinger S *et al.* Early intravenous thrombolysis for acute ischaemic stroke in a community-based approach. *Stroke* 1998; 29: 1544–9.
25. Liu M, Fisher M, Yuan G, Zheng H. Early presentation of acute stroke in a Chinese population. *Cerebrovasc Dis* 1995; 5: 362–5.
26. Lin CS, Tsai J, Woo P, Chang H. Prehospital delay and emergency department management of ischemic stroke patients in Taiwan, R.O.C. *Prehosp Emerg Care* 1999; 3: 194–200.
27. Yoneda Y, Tabuchi M, Ohsumi Y *et al.* Pre- and in-hospital emergency systems for acute ischaemic stroke in a Japanese hospital. *J Stroke Cerebrovasc Dis* 2000; 9: 297–8.
28. Fogelholm R, Murros K, Rissanen A, Ilmavirta M. Factors delaying hospital admission after acute stroke. *Stroke* 1996; 27: 398–400.
29. Anderson NE, Broad JB, Bonita R. Delays in hospital admission and investigation in acute stroke. *Br Med J* 1995; 311: 162.
30. Bratina P, Greendberg L, Pasteur W, Grotta JC. Current emergency department management of stroke in Houston, Texas. *Stroke* 1995; 26: 409–14.
31. Casetta I, Granieri E, Gilli G, Laura G, Tola MR, Paolino E. Temporal trend and factors associated with delayed hospital admission of stroke patients. *Neuroepidemiology* 1999; 18: 255–64.
32. Lannehoa Y, Bouget J, Pinel JF, Garnier N, Leblanc JP, Branger B. Analysis of time management in stroke patients in three French emergency departments from stroke onset to computed tomography scan. *Eur J Emerg Med* 1999; 6: 95–103.
33. Mayer-Reichenauer M, Dachenhausen A, Bosak P *et al.* Prospective study of factors delaying admission to a stroke unit: the need for public education and training programmes for emergency physicians and paramedics. *Cerebrovasc Dis* 1998; 8: 35 [Abstract CLI 43].
34. Morris DL, Rosamond W, Madden K, Schultz C, Hamilton S. Prehospital and emergency department delays after acute stroke: The Genentech Stroke Presentation Survey. *Stroke* 2000; 31: 2585–90.
35. Pistollato G, Ermani M. Time of hospital presentation after stroke. A multicenter study in north-east Italy. *Ital J Neurol Sci* 1996; 17: 401–7.

36. Rosamond WD, Gorton RA, Hinn AR, Hohenhaus SM, Morris DL. Rapid response to stroke symptoms: the Delay in Accessing Stroke Healthcare (DASH) Study. *Acad Emerg Med* 1998; 5: 45–51.
37. Hodgson C. Emergency management of acute ischaemic stroke in Canadian hospitals. *CMAJ* 1998; 159: S15–S18.
38. Morris DL, Rosamond W, Hinn AR, Gorton RA. Time delays in accessing stroke care in the emergency department. *Acad Emerg Med* 1999; 6: 218–23.
39. Charleston AJ, Barber PA, Bennett P, Spriggs DA, Harris RG, Anderson NE. Management of stroke in Auckland Hospital in 1996. *N Z Med J* 1999; 112: 71–4.
40. Salisbury HR, Banks BJ, Footitt DR, Winner SJ, Reynolds DJM. Delay in presentation of patients with acute stroke to hospital in Oxford. *Q J Med* 1998; 91: 635–40.
41. Smith MA, Doliszny KM, Shahar E, McGovern PG, Arnett DK, Luepker RV. Delayed hospital arrival for acute stroke: the Minnesota Stroke Survey. *Ann Intern Med* 1998; 129: 190–6.
42. Harper GD, Haigh RA, Potter JF, Castleden CM. Factors delaying hospital admission after stroke in Leicestershire. *Stroke* 1992; 23: 835–8.
43. Alberts MJ, Bertels C, Dawson DV. An analysis of time of presentation after stroke. *JAMA* 1990; 263: 65–8.
44. Biller J, Patrick JT, Shepard A, Adams HP. Delay time between onset of ischemic stroke and hospital arrival. *J Stroke Cerebrovasc Dis* 1993; 3: 228–30.
45. Kay R, Woo J, Poon WS. Hospital arrival time after onset of stroke. *J Neurol Neurosurg Psychiatr* 1992; 55: 973–4.
46. Duncan PW, Harrison DJ, Lai SM, Cook SF, Rymer MM. Factors affecting elapsed time between acute stroke and presentation. *Stroke* 2000; 31: 308 [Abstract P60].
47. Engelstein E, Margulies J, Jeret JS. Lack of t-PA use for acute ischaemic stroke in a community hospital: high incidence of exclusion criteria. *Am J Emerg Med* 2000; 18: 257–60.
48. Johnston F, Wardlaw J, Dennis MS *et al.* Delays in stroke referrals. *Lancet* 1999; 354: 47–48.
49. Schroeder EB, Rosamond WD, Morris DL, Evenson KR, Hinn AR. Determinants of use of emergency medical services in a population with stroke symptoms : the second Delay in Accessing Stroke Healthcare (DASH II) Study. *Stroke* 2000; 31: 2591–6.
50. Williams LS, Bruno A, Rouch D, Marriott DJ. Stroke patients' knowledge of stroke. Influence on time of presentation. *Stroke* 1997; 28: 912–15.
51. Menon SC, Pandey DK, Morgenstern LB. Critical factors determining access to acute stroke care. *Neurology* 1998; 51: 427–32.
52. Wein TH, Staub L, Felberg R *et al.* Activation of emergency medical services for acute stroke in a nonurban population: the T.L.L. Temple Foundation Stroke Project. *Stroke* 2000; 31: 1925–8.
53. Barsan WG, Brott TG, Broderick JP, Haley EC Jr., Levy DE, Marler JR. Urgent therapy for acute stroke. Effects of a stroke trial on untreated patients. *Stroke* 1994; 25: 2132–7.
54. Bartolini M, Ceravolo MG, Polonara S, Polonara G, Reginelli R, Provinciali L. Thrombolysis in ischemic stroke: evaluation of operative difficulties. *Arch Gerontolgy Geriatr* 1995; 20: 49–54.
55. Herderschee D, Limburg M, Hijdra A, Bollen A, Pluvier J, te Water W. Timing of hospital admission in a prospective series of stroke patients. *Cerebrovasc Dis* 1991; 1: 165–7.
56. Andre C, Moraes-Neto BM, Novis SAP. Experience with t-PA treatment in a large south American city. *J Stroke Cerebrovasc Dis* 1998; 7: 255–8.
57. Malik MM, Gomez CR, Tulyapronchote R, Malkoff MD, Bandlamudi R, Banet GA. Delay between emergency room arrival and stroke consultation. *J Stroke Cerebrovasc Dis* 1993; 3: 177–80.
58. Villar-Cordova C, Morgenstern LB, Barnholtz JS, Frankowski RF, Grotta JC. Neurologists' attitudes regarding rt-PA for acute ischemic stroke. *Neurology* 1998; 50: 1491–4.
59. Kothari R, Barsan W, Brott T, Broderick J, Ashbrock S. Frequency and accuracy of prehospital diagnosis of acute stroke. *Stroke* 1995; 26: 937–41.
60. Bornstein N, Karepov VG. A call for improvement in prehospital stroke identification. *Stroke* 2000; 31: 309 [Abstract P65].
61. Chiu D, Krieger D, Villar-Cordova C *et al.* Intravenous tissue plasminogen activator for acute ischaemic stroke. Feasibility, safety, and efficacy in the first year of clinical practice. *Stroke* 1998; 29: 18–22.
62. Evenson KR, Rosamond W, Morris DL. Prehospital and in-hospital delays in acute stroke care. *Neuroepidemiology* 2001; 20: 65–76.
63. Gorelick PB, Sacco RL, Smith DB *et al.* Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. *JAMA* 1999; 281: 1112–20.
64. Weltermann BM, Rogalewski A, Homann J *et al.* Knowledge about stroke among the German population. *Dtsch Med Wochenschr* 2000; 125: 416–20.
65. Kaste M, Skyhoj OT, Orgogozo J, Bogousslavsky J, Hacke W. Organization of stroke care: education, stroke units and rehabilitation. European Stroke Initiative (EUSI). *Cerebrovasc Dis* 2000; 10 (Suppl 3): 1–11.
66. Kaste M. Thrombolysis in ischaemic stroke – present and future: role of combined therapy. *Cerebrovasc Dis* 2001; 11 (Suppl 1): 55–9.
67. Morgenstern LB, Staub L, Chan W *et al.* Improving delivery of acute stroke therapy: The TLL Temple Foundation Stroke Project. *Stroke* 2002; 33: 160–6.

Received 12 February 2003; accepted 18 September 2003